Inventiva S.A.
Inventiva develops lanifibranor, a pan-PPAR agonist small molecule in Phase 3 trials for metabolic dysfunction-associated steatohepatitis.
6-KSep 28Latest SEC filing
Sep 28Latest story
Sign inSign inInventiva develops lanifibranor, a pan-PPAR agonist small molecule in Phase 3 trials for metabolic dysfunction-associated steatohepatitis.
September 2026
August 2026
July 2026